NewLimit
Signal active
Organization
Contact Information
Overview
NewLimit specializes in treating age-related diseases to extend the human health span. It works on developing epigenetic reprogramming medicines to treat diseases with large unmet needs.
About
Industries
Biotechnology, Health Care, Clinical Trials
Founded
2022
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
NewLimit headquartered in United States, North America, operates in the Biotechnology, Health Care, Clinical Trials sector. The company focuses on Biotechnology and has secured $480.0M in funding across 12 round(s). With a team of 11-50 employees, NewLimit is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - NewLimit, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
7
Lead Investors
0
Total Funding Amount
$40.0M
Details
1
NewLimit has raised a total of $40.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Early Stage Venture | 40.0M |
Investors
NewLimit is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Garry Tan | - | FUNDING ROUND - Garry Tan | 40.0M |
| Kleiner Perkins | - | FUNDING ROUND - Kleiner Perkins | 40.0M |
| NewLimit | - | FUNDING ROUND - NewLimit | 40.0M |
| Elad Gil | - | FUNDING ROUND - Elad Gil | 40.0M |
Recent Activity
There is no recent news or activity for this profile.